On September 29, 2025 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), reported that the US Patent and Trademark Office (USPTO) has notified the Company that a key patent protecting the Company’s best-in-class FAK inhibitor narmafotinib has been allowed in the US (Press release, Amplia Therapeutics, SEP 29, 2025, View Source [SID1234656325]). The patent, titled A salt and crystal form of a FAK Inhibitor, describes the specific chemical form of narmafotinib being utilised in currently ongoing clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent allowance precedes a formal ‘Notification of Grant’ of the patent, which is expected in the coming months. The Company has previously announced that this key patent has already been granted in Japan and Europe1, and it has also been granted in Australia, India, Korea, Singapore, and New Zealand. Granting of this patent extends protection of narmafotinib out to a least 2040 in these jurisdictions. Protection in other regions is under review by the respective patent offices.

This patent describes a stable, manufacturable form of narmafotinib that provides improved drug levels upon dosing. Importantly, it is this specific form of the drug that is being developed clinically by the Company, including in the current ACCENT and AMPLICITY trials in advanced pancreatic cancer.

Amplia’s CEO and Managing Director Dr Chris Burns comments: "We continue to build a patent portfolio around narmafotinib to ensure the Company’s key intellectual property is protected and thus commercially valuable, for as long as possible."